176 related articles for article (PubMed ID: 38375992)
21. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
Rambout L; Hopkins L; Hutton B; Fergusson D
CMAJ; 2007 Aug; 177(5):469-79. PubMed ID: 17671238
[TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus-associated cutaneous disease burden in human immunodeficiency virus (HIV)-positive patients: the role of human papillomavirus vaccination and a review of the literature.
Bacik LC; Chung C
Int J Dermatol; 2018 Jun; 57(6):627-634. PubMed ID: 29152727
[TBL] [Abstract][Full Text] [Related]
23. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
[TBL] [Abstract][Full Text] [Related]
24. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer.
Tjalma WA; Arbyn M; Paavonen J; van Waes TR; Bogers JJ
Int J Gynecol Cancer; 2004; 14(5):751-61. PubMed ID: 15361181
[TBL] [Abstract][Full Text] [Related]
26. Human papillomavirus genotypic characteristics of 60,685 subjects under age-expansion vaccination of the nine-valent human papillomavirus vaccine: A cross-sectional study.
Liu Y; Li Z; Yuan L; Liu F; Wu K; Xiao X; Zhu C
J Infect Public Health; 2023 Jul; 16(7):989-995. PubMed ID: 37167646
[TBL] [Abstract][Full Text] [Related]
27. Exploring individual HPV coinfections is essential to predict HPV-vaccination impact on genotype distribution: a model-based approach.
Pons-Salort M; Letort V; Favre M; Heard I; Dervaux B; Opatowski L; Guillemot D
Vaccine; 2013 Feb; 31(8):1238-45. PubMed ID: 23246257
[TBL] [Abstract][Full Text] [Related]
28. Assessing the risk of cervical neoplasia in the post-HPV vaccination era.
Lehtinen M; Pimenoff VN; Nedjai B; Louvanto K; Verhoef L; Heideman DAM; El-Zein M; Widschwendter M; Dillner J
Int J Cancer; 2023 Mar; 152(6):1060-1068. PubMed ID: 36093582
[TBL] [Abstract][Full Text] [Related]
29. The role of human papillomavirus in the malignant transformation of cervix epithelial cells and the importance of vaccination against this virus.
Ciesielska U; Nowińska K; Podhorska-Okołów M; Dziegiel P
Adv Clin Exp Med; 2012; 21(2):235-44. PubMed ID: 23214288
[TBL] [Abstract][Full Text] [Related]
30. Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine.
Monsonego J; Cortes J; Greppe C; Hampl M; Joura E; Singer A
Vaccine; 2010 Nov; 28(51):8065-72. PubMed ID: 20971114
[TBL] [Abstract][Full Text] [Related]
31. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine.
Goldie SJ; Grima D; Kohli M; Wright TC; Weinstein M; Franco E
Int J Cancer; 2003 Oct; 106(6):896-904. PubMed ID: 12918067
[TBL] [Abstract][Full Text] [Related]
32. Human Papillomavirus Vaccine: The Cancer Prevention Moonshot.
Petrie K; Wells A; Eckert LO
Obstet Gynecol Clin North Am; 2023 Jun; 50(2):339-348. PubMed ID: 37149314
[TBL] [Abstract][Full Text] [Related]
33. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.
Goldstone SE; Vuocolo S
Expert Rev Vaccines; 2012 Apr; 11(4):395-406. PubMed ID: 22551023
[TBL] [Abstract][Full Text] [Related]
34. HPV vaccination: the beginning of the end of cervical cancer? - A Review.
Lepique AP; Rabachini T; Villa LL
Mem Inst Oswaldo Cruz; 2009 Feb; 104(1):1-10. PubMed ID: 19274369
[TBL] [Abstract][Full Text] [Related]
35. Human papillomavirus genotype distribution among women with and without cervical cancer: Implication for vaccination and screening in Ghana.
Nartey Y; Amo-Antwi K; Hill PC; Dassah ET; Asmah RH; Nyarko KM; Agambire R; Konney TO; Yarney J; Damale N; Cox B
PLoS One; 2023; 18(1):e0280437. PubMed ID: 36656844
[TBL] [Abstract][Full Text] [Related]
36. Molecular pathogenesis of cervical cancer.
Ibeanu OA
Cancer Biol Ther; 2011 Feb; 11(3):295-306. PubMed ID: 21239888
[TBL] [Abstract][Full Text] [Related]
37. Clinical trials of human papillomavirus vaccines and beyond.
Lehtinen M; Dillner J
Nat Rev Clin Oncol; 2013 Jul; 10(7):400-10. PubMed ID: 23736648
[TBL] [Abstract][Full Text] [Related]
38. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
39. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management.
Brinkman JA; Caffrey AS; Muderspach LI; Roman LD; Kast WM
Eur J Gynaecol Oncol; 2005; 26(2):129-42. PubMed ID: 15857016
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic HPV vaccines.
Hancock G; Hellner K; Dorrell L
Best Pract Res Clin Obstet Gynaecol; 2018 Feb; 47():59-72. PubMed ID: 29108943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
